Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
$2.90
+0.9%
$3.69
$2.77
▼
$21.73
$569.01M-1.43.66 million shs1.12 million shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
-8.31%-17.53%-8.31%-45.75%-59.46%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
$2.90
+0.9%
$3.69
$2.77
▼
$21.73
$569.01M-1.43.66 million shs1.12 million shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
-8.31%-17.53%-8.31%-45.75%-59.46%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
2.90
Moderate Buy$20.44634.09% Upside

Current Analyst Ratings Breakdown

Latest WVE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/12/2026
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
Lower Price TargetBuy$19.00 ➝ $15.00
11/9/2026
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
Reiterated RatingBuy$18.00
10/28/2026
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
Initiated CoverageStrong-Buy
10/27/2026
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
Set Price Target$10.00
10/16/2026
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
Initiated CoverageOutperform
10/15/2026
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
Reiterated RatingSell (D-)
10/15/2026
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
Initiated CoverageBuy$11.00
10/14/2026
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
UpgradeStrong-Buy
10/2/2026
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
Set Price Target$13.00
10/2/2026
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
Reiterated RatingBuy
(Data available from 11/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
$70.92M7.74N/AN/A$2.04 per share1.37
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
-$204.38M-$1.07N/AN/AN/A-296.86%-44.66%-36.80%N/A

Latest WVE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/27/2026Q3 2026
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
-$0.3290-$0.30+$0.0290-$0.30$4.51 million$13.16 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
N/A
8.38
8.38

Institutional Ownership

CompanyInstitutional Ownership
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
89.73%

Insider Ownership

CompanyInsider Ownership
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
24.34%
CompanyEmployeesShares OutstandingFree FloatOptionable
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
317197.23 million149.22 millionOptionable

Recent News About These Companies

Wave Life Sciences stock highlights WVE-007 obesity data
WAVE Life Sciences (NASDAQ:WVE) Reaches New 12-Month Low on Analyst Downgrade
Wave: 3 Key Takeaways for Long-Term Investors
Transcript : Wave Life Sciences, Inc. - Special Call
Wave Life Sciences stock enters key week after Q3 update

New MarketBeat Followers Over Time

Media Sentiment Over Time

WAVE Life Sciences stock logo

WAVE Life Sciences NASDAQ:WVE

$2.88 +0.01 (+0.52%)
As of 12:52 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.